Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ CM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Opexa Therapeutics Inc

+ Add to Watchlist

OPXA:US

0.4100 USD 0.0100 2.38%

As of 20:10:00 ET on 04/20/2015.

Snapshot for Opexa Therapeutics Inc (OPXA)

Open: 0.4350 Day's Range: 0.4100 - 0.4350 Volume: 430,084
Previous Close: 0.4200 52wk Range: 0.4011 - 1.6220 1-Yr Rtn: -72.18%

Stock Chart for OPXA

No chart data available.
  • OPXA:US 0.4100
  • 1D
  • 1M
  • 1Y
0.4200
Interactive OPXA Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for OPXA

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.5005
Est. EPS (USD) (12/2015) -
Est. PEG Ratio -
Market Cap (M USD) 21.87
Shares Outstanding (M) 53.33
30 Day Average Volume 596,478
Price/Book (mrq) 1.6790
Price/Sale (ttm) 9.6411
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/14/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for OPXA

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for OPXA

Opexa Therapeutics, Inc. is biotechnology company. The company develops cellular therapies for the treatment of multiple sclerosis, rheumatoid arthritis, pancreatic, and cardiac conditions. Opexa holds a worldwide license for an autologous T cell vaccine for rheumatoid arthritis.

Neil K WarmaPresident/CEOKarthik RadhakrishnanChief Financial Officer
Donna R RillChief Development Officer
More Company Profile & Key Executives for OPXA

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil